Vera Therapeutics (VERA) Cash & Equivalents (2020 - 2026)

Vera Therapeutics (VERA) has 7 years of Cash & Equivalents data on file, last reported at $114.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 107.57% year-over-year to $114.4 million; the trailing twelve-month figure through Mar 2026 stood at $114.4 million (up 107.57% YoY), and the FY2025 full-year result was $354.7 million, up 282.88% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $114.4 million, down from $354.7 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $354.7 million in Q4 2025 and bottomed at $25.1 million in Q2 2024.
• The 5-year median for Cash & Equivalents is $50.4 million (2022), against an average of $78.0 million.
• The widest annual swing landed in 2022, when Cash & Equivalents sank 64.64%; it then jumped 282.88% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $43.5 million in 2022, then gained by 5.11% to $45.7 million in 2023, then jumped by 102.81% to $92.6 million in 2024, then surged by 282.88% to $354.7 million in 2025, then plunged by 67.76% to $114.4 million in 2026.
• The last three Cash & Equivalents figures came in at $114.4 million (Q1 2026), $354.7 million (Q4 2025), and $57.8 million (Q3 2025), per Business Quant data.

Peer Comparison